<DOC>
	<DOCNO>NCT00479180</DOCNO>
	<brief_summary>Vascugel™ safe place anastomotic site time surgery creation AV graft fistula hemodialysis access .</brief_summary>
	<brief_title>Safety Vascugel Treatment After Creation Arteriovenous Access Hemodialysis Use</brief_title>
	<detailed_description>Randomized , double-blind , parallel group , Phase I/II clinical trial Vascugel™ treatment vs. Gelfoam® patient undergo creation arteriovenous graft fistula hemodialysis access . All patient undergo preoperative duplex ultrasound image and/or angiography ( whatever standard care research site ) vein artery evaluate optimal site vascular access placement upper extremity . Patients examine Doppler ultrasound standard care immediately surgery verify patency AV graft fistula . During follow-up period , patient undergo physical examination image vascular access specify interval .</detailed_description>
	<criteria>Adult male female patient ( age 18 89 , inclusive ) undergo placement AV graft fistula hemodialysis access Patient currently active transplant list kidney decease donor OR undergoing assessment expect place active transplant list within next twentyfour week OR expect receive living donor kidney within twentyfour week . Patient expect another solid organ transplant bone marrow transplant . Patient one access surgery ( defined new access , revision ) target limb . Patient currently chronic , systemic immunosuppressant medication locally topically applied steroid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Hemodialysis access</keyword>
	<keyword>Arteriovenous graft</keyword>
	<keyword>Arteriovenous fistula</keyword>
	<keyword>End stage renal disease</keyword>
</DOC>